344 related articles for article (PubMed ID: 30140420)
1. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
Mol Autism; 2018; 9():45. PubMed ID: 30140420
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.
Huang HS; Allen JA; Mabb AM; King IF; Miriyala J; Taylor-Blake B; Sciaky N; Dutton JW; Lee HM; Chen X; Jin J; Bridges AS; Zylka MJ; Roth BL; Philpot BD
Nature; 2011 Dec; 481(7380):185-9. PubMed ID: 22190039
[TBL] [Abstract][Full Text] [Related]
3. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
[TBL] [Abstract][Full Text] [Related]
4. R-loop formation at Snord116 mediates topotecan inhibition of Ube3a-antisense and allele-specific chromatin decondensation.
Powell WT; Coulson RL; Gonzales ML; Crary FK; Wong SS; Adams S; Ach RA; Tsang P; Yamada NA; Yasui DH; Chédin F; LaSalle JM
Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13938-43. PubMed ID: 23918391
[TBL] [Abstract][Full Text] [Related]
5. Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
Tsagkaris C; Papakosta V; Miranda AV; Zacharopoulou L; Danilchenko V; Matiashova L; Dhar A
Curr Gene Ther; 2020; 19(6):359-366. PubMed ID: 31914913
[TBL] [Abstract][Full Text] [Related]
6. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model.
Meng L; Person RE; Huang W; Zhu PJ; Costa-Mattioli M; Beaudet AL
PLoS Genet; 2013; 9(12):e1004039. PubMed ID: 24385930
[TBL] [Abstract][Full Text] [Related]
7. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome.
Sonzogni M; Zhai P; Mientjes EJ; van Woerden GM; Elgersma Y
Mol Autism; 2020 Sep; 11(1):70. PubMed ID: 32948244
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Nociception in Angelman Syndrome Model Mice.
McCoy ES; Taylor-Blake B; Aita M; Simon JM; Philpot BD; Zylka MJ
J Neurosci; 2017 Oct; 37(42):10230-10239. PubMed ID: 28931574
[TBL] [Abstract][Full Text] [Related]
9. Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA.
Wolter JM; Mao H; Fragola G; Simon JM; Krantz JL; Bazick HO; Oztemiz B; Stein JL; Zylka MJ
Nature; 2020 Nov; 587(7833):281-284. PubMed ID: 33087932
[TBL] [Abstract][Full Text] [Related]
10. Persistent neuronal Ube3a expression in the suprachiasmatic nucleus of Angelman syndrome model mice.
Jones KA; Han JE; DeBruyne JP; Philpot BD
Sci Rep; 2016 Jun; 6():28238. PubMed ID: 27306933
[TBL] [Abstract][Full Text] [Related]
11. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the
Dindot SV; Christian S; Murphy WJ; Berent A; Panagoulias J; Schlafer A; Ballard J; Radeva K; Robinson R; Myers L; Jepp T; Shaheen H; Hillman P; Konganti K; Hillhouse A; Bredemeyer KR; Black L; Douville J; ;
Sci Transl Med; 2023 Mar; 15(688):eabf4077. PubMed ID: 36947593
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice.
Schmid RS; Deng X; Panikker P; Msackyi M; Breton C; Wilson JM
J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33411694
[TBL] [Abstract][Full Text] [Related]
13. Ube3a imprinting impairs circadian robustness in Angelman syndrome models.
Shi SQ; Bichell TJ; Ihrie RA; Johnson CH
Curr Biol; 2015 Mar; 25(5):537-45. PubMed ID: 25660546
[TBL] [Abstract][Full Text] [Related]
14. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Burton JH; Mazcko C; LeBlanc A; Covey JM; Ji J; Kinders RJ; Parchment RE; Khanna C; Paoloni M; Lana S; Weishaar K; London C; Kisseberth W; Krick E; Vail D; Childress M; Bryan JN; Barber L; Ehrhart EJ; Kent M; Fan T; Kow K; Northup N; Wilson-Robles H; Tomaszewski J; Holleran JL; Muzzio M; Eiseman J; Beumer JH; Doroshow JH; Pommier Y
Clin Cancer Res; 2018 Dec; 24(23):5830-5840. PubMed ID: 30061364
[TBL] [Abstract][Full Text] [Related]
15. Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a.
Meng L; Person RE; Beaudet AL
Hum Mol Genet; 2012 Jul; 21(13):3001-12. PubMed ID: 22493002
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological therapies for Angelman syndrome.
Tan WH; Bird LM
Wien Med Wochenschr; 2017 Jun; 167(9-10):205-218. PubMed ID: 26758979
[TBL] [Abstract][Full Text] [Related]
17. Angelman syndrome-derived neurons display late onset of paternal UBE3A silencing.
Stanurova J; Neureiter A; Hiber M; de Oliveira Kessler H; Stolp K; Goetzke R; Klein D; Bankfalvi A; Klump H; Steenpass L
Sci Rep; 2016 Aug; 6():30792. PubMed ID: 27484051
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome.
Lee D; Chen W; Kaku HN; Zhuo X; Chao ES; Soriano A; Kuncheria A; Flores S; Kim JH; Rivera A; Rigo F; Jafar-Nejad P; Beaudet AL; Caudill MS; Xue M
Elife; 2023 Jan; 12():. PubMed ID: 36594817
[No Abstract] [Full Text] [Related]
19. A bipartite boundary element restricts
Hsiao JS; Germain ND; Wilderman A; Stoddard C; Wojenski LA; Villafano GJ; Core L; Cotney J; Chamberlain SJ
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2181-2186. PubMed ID: 30674673
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
Pfister TD; Hollingshead M; Kinders RJ; Zhang Y; Evrard YA; Ji J; Khin SA; Borgel S; Stotler H; Carter J; Divelbiss R; Kummar S; Pommier Y; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2012; 7(12):e50494. PubMed ID: 23284638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
